472:, with plans to retain all 170 employees thereat. However, the company ran into financial trouble originating from several quarters, and a decision to sell the facility was reached in late 2009, after Genmab had started producing development scale batches from the facility. In 2008, the world was experiencing a financial crisis as a whole, and GlaxoSmithKline decided to exit oncology, which impacted co-development of ofatumumab, an oncology-directed product. In tandem with the sale of the plant, the company reorganized and planned to dismiss about 300 employees. Selling the facility, though, proved very difficult, due in large part to the global financial crisis; by 2012, Genmab had decided to simply
1970:
2468:
432:, provided the seed investment for the company to start up in Copenhagen. Like Medarex, Genmab began work producing monoclonal antibodies for life-threatening or debilitating diseases. Rising quickly in the Biotech world, Genmab attracted many investors, especially venture capital firms. The company went public in October 2000, earning DKK 1.56 billion, and had a second public offering in January 2006, yielding DKK 800 million.
404:
technology is called the HuMab-Mouse technology. One benefit of using this type of technology is that there is no need for humanization or complicated genetic engineering to make this antibody fit for humans which cuts down on expenses and time spent developing it. It can be generated within months and can be selected to bind to specific antigens such as tumor cells and other infectious agents.
22:
525:
agreement to a new antibody program targeting additional disease targets. Amgen has discontinued development of the IL15 antibody, AMG 714, in psoriasis and rheumatoid arthritis based on disappointing results from recent clinical studies. Amgen is exploring options to maximize the value of this asset, but as this time, no further internal development of a lead indication is planned.
88:
566:) if all milestones are reached and commercial success is reached in the fields of cancer, autoimmune, and inflammatory disease. The intention of GlaxoSmithKline to exit oncology, disagreement around milestones reached, and financial difficulties of Genmab, led to re-negotiation of the partnership in mid-2010, resulting in an immediate
415:
antibody. Normally the IgG4 is considered inert and doesnât elicit an immune response. However, they are also unstable and fall apart easily, which makes them unsuitable for therapeutic use. Genmab changes the shape of the IgG4 antibody by eliminating the hinge, the part of the antibody that creates
403:
to create fully human high affinity antibodies using transgenic mice. These antibodies are less likely to elicit an allergic reaction and other side effects compared with other types of man-made antibodies containing other animal proteins because the IgG antibodies produced have human proteins. This
524:
In May 1999, Genmab entered a sub-license agreement with Amgen where it would gain rights to the IL15 antibodies. In
October 2001, this was replaced by a direct license agreement where Amgen retained exclusive commercialization options for the products through phase II. Amgen has also expanded its
407:
Genmab also has developed its own technology called UniBody, which is used to make smaller antibodies in contrast to the traditional full sized monoclonal antibody. Its smaller size allows for better distribution over larger target areas like tumors. The UniBody can only bind to one site and doesnât
2368:
408:
elicit a harmful immune response by binding to two sites and over-activating cell growth. It does not kill target cells but rather silences or inhibits them. Thus it can be used to treat certain cancers, inflammations, allergies and asthmas, where killing the cell isnât the objective.
513:(CSO); he had concurrently served as head of research, then president of R&D. As of 2019, Van de Winkel remained CEO of the firm. Van de Winkel is a scientist, having produced more than 300 publications during his career.
1764:
2022-11: FDA has advised ADCT that an ongoing ph3 study - preferably with full enrollment - is needed to support a BLA submission. ADCT therefore plans to conduct a ph3 study for which full enrollment is estimated to take 2
2369:"EPKINLYâą (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)"
446:
By 2001, Medarex and Genmab had come back together in a drug development partnership, which highlighted the manufacturing deficit and clinical development expertise of Genmab relative to
Medarex.
454:
2417:
416:
the âYâ shape. This halves the antibody, creating a smaller version now known as their UniBody. This smaller version can only bind to one site and does not stimulate cancer cells to grow.
502:(CEO) of the company upon incorporation in 1999, also joining the board of directors. As of 2002, Drakeman remained in the CEO role, but by 2010 she had announced her retirement.
2631:
2434:
458:
429:
483:
Following the failed strategy of in-housing manufacturing, Genmab chose to thereafter completely outsource both manufacturing and the conduct of clinical trials.
2135:
2915:
2456:
2920:
2940:
2910:
1754:
340:, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in
2245:
2890:
2464:
2925:
2193:
2900:
2945:
2905:
2109:
2226:. Vol. XXVI, no. 324. Minneapolis, Minnesota: The Star Tribune Company. Dow Jones News Service. February 22, 2008. p. D2
2449:
443:, in June 2018. By mid-2019, this new facility was at capacity, and plans were set afoot to build an adjacent, connected facility.
2950:
2895:
2638:
1702:
804:
700:
486:
The
Company's first product, Arzerra (ofatumumab) reached the US market in 2009 for refractory chronic lymphocytic leukemia.
2442:
2328:
1885:
547:
2418:"Confirmatory Phase 3 Trial Needed Prior to Camidanlumab Tesirine BLA Submission for Accelerated Approval Path, FDA Says"
2011:
543:
450:
284:
759:
Furthermore both Genmab and its partners have a whole range of antibody programs, building on Genmab technologies, in
2143:
1859:
64:
2354:
1487:
2272:
2219:
764:
2395:
2935:
597:
1845:
898:
627:
1568:
1057:
2249:
2033:
1911:
1429:
1061:
506:
207:
128:
2301:
1144:
715:
498:, Medarex's CEO and President at the time. Drakeman was one of Genmab's co-founders and was appointed
116:
2059:
1517:
1466:
1362:
748:
677:
381:
237:
37:
1707:
1632:
808:
510:
465:
573:
In addition, Genmab has collaborations with Roche (RG1507, a monoclonal antibody directed against
1815:
1373:
689:
570:
payment by GlaxoSmithKline and future financial and licensing concessions on the part of Genmab.
499:
211:
46:
2197:
2930:
2624:
2580:
673:
2113:
2844:
1742:
1683:
820:
361:
337:
2166:
1526:
1036:
828:
782:
752:
737:
726:
665:
551:
477:
436:
8:
2809:
2712:
1687:
996:
824:
786:
593:
2707:
2605:
1569:
Pipeline, Partner-owned products incorporating Genmabâs innovation, â„Phase 2 Development
464:
2008 saw the company purchasing a 22,000-litre, 36-acre antibody manufacturing plant in
1165:
605:
495:
2575:
2472:
2084:
1655:
1610:
1460:
910:
800:
638:
580:
In April 2024, the company announced it would acquire
ProfoundBio for $ 1.8 billion.
265:
133:
124:
32:
554:
and other indications. The agreement gave Genmab a license fee of DKK 582 million (
1378:
1312:
926:
895:
876:
681:
642:
624:
476:
the entire facility from the company's balance sheets. A sale of the facility to
2667:
2505:
2500:
1805:
1789:
944:
933:
770:
649:
540:
532:
684:
as combination therapy or monotherapy, and for the treatment of newly diagnosed
2662:
2600:
2490:
1778:
1606:
1401:
796:
774:
760:
685:
349:
98:
2308:. Vol. 270, no. 173. Associated Press. December 20, 2006. p. D5
2884:
2864:
2854:
2829:
2697:
2687:
2647:
2585:
2540:
2530:
1727:
915:
812:
469:
365:
144:
112:
106:
1324:
509:
and CEO of Genmab. Since the company started in 1999, he had been Genmab's
388:
2702:
2565:
2173:. Vol. 119, no. 23. Bridgewater, New Jersey: Gannett. p. A11
1722:
1444:
1224:
Genmab (under an exclusive worldwide license/option agreement with
Janssen)
792:
791:
The partners have, among others, clinical programs for daratumumab (non-MM
744:
275:
261:
2616:
1852:
2819:
2794:
2789:
2763:
2682:
2672:
2560:
2520:
2510:
1773:
1541:
1511:
1481:
1358:
870:
733:
722:
711:
669:
616:
494:
Lisa N. Drakeman, Ph.D. had been a vice president at
Medarex and wife of
439:, in the Netherlands; this was replaced with an "R&D Center" also in
353:
257:
253:
249:
241:
232:
218:
769:
Genmab have several late stage clinical programs for tisotumab vedotin (
2814:
2784:
2758:
2550:
1673:
1668:
1415:
930:
816:
696:
646:
536:
505:
In 2010, Jan Van de Winkel, a co-founder of the firm, was appointed as
341:
296:
245:
180:
424:
Genmab was founded as a
European spin-off of American Biotech company
2834:
2677:
2570:
2515:
1713:
473:
2196:(Press release). Biotechnology Industry Organization. Archived from
562:). The potential value of this agreement could be DKK 12.0 billion (
435:
The company's initial R&D location was a nine-story building in
2849:
2799:
2037:
1810:
1717:
1424:
1268:
1139:
1114:
778:
704:
589:
558:) and GSK bought 4,471,202 shares of Genmab for DKK 2,033 million (
344:, Denmark â internationally, it operates through the subsidiaries
2824:
2555:
2545:
2476:
2467:
2040:). US Securities and Exchange Commission. March 5, 1999. Contacts
891:
620:
440:
425:
400:
380:. Genmab is a dual-listed company with shares traded on both the
334:
2804:
2748:
2728:
2595:
2525:
2495:
2355:"Novartis, Ono Latest to Announce Billion-Dollar M&A Deals"
1783:
1678:
1547:
1450:
1033:
921:
886:
653:
631:
601:
574:
385:
120:
2012:"Rooted in Science, Inspired by Patients - 2023 Annual Report"
945:
Pipeline, Including
Further Development for Approved Medicines
2869:
2859:
2753:
2743:
2738:
2194:"James D. Watson Helix Awards Honor Biotech's Top Performers"
1749:
1491:
1455:
1241:
1133:
1129:
377:
373:
428:
in
February 1999. Danish investment firm BankInvest, under
2733:
2590:
2273:"Roche expands commitment to innovative advanced medicines"
1971:"The 5-Step Strategy That Saved Genmab From A Dire Outlook"
1964:
1962:
1960:
1958:
1956:
1954:
1952:
1904:
1368:
1262:
1219:
1197:
880:
412:
2279:. Nutley, New Jersey: North Jersey Media Group. p. 10
1950:
1948:
1946:
1944:
1942:
1940:
1938:
1936:
1934:
1932:
2839:
2779:
2396:"Morgan Stanley 20th Annual Global Healthcare Conference"
1325:
321:
87:
1929:
1768:
5-9% tiered (GMAB: "mid-to-high single-digit tiered")
2390:
2388:
2386:
2329:"Genmab shares slide after Roche dumps collaboration"
1387:
0-$ 3bn tiered: 14.92% (avg.), >$ 3bn fixed: 20%
767:
development in both cancer and autoimmune diseases.
2383:
2882:
1329:
2264:
844:
42:A mess of an article whose lede is a disaster.
2632:
2450:
1878:
1860:"Biotekstjerne spottede de gode forretninger"
1737:5-6% (Jan Van de Winkel: "mid single-digit")
1697:5-6% (Jan Van de Winkel: "mid single-digit")
1582:Discovered and/or Developed & Marketed By
1343:Discovered and/or Developed & Marketed By
539:, a drug that could be used for treatment in
531:In December 2006, Genmab entered a deal with
2916:Pharmaceutical companies established in 1999
718:(EGFR exon 20 insertion mutations) (Janssen)
2921:Biotechnology companies established in 1999
2646:
2371:(Press release). globenewswire. 19 May 2023
2941:Companies based in Copenhagen Municipality
2911:Life science companies based in Copenhagen
2639:
2625:
2457:
2443:
2102:
2420:. www.cancernetwork.com. 11 November 2022
65:Learn how and when to remove this message
2192:Debbie, Strickland (February 24, 2005).
2006:
2004:
2002:
2000:
1998:
1996:
1994:
1992:
641:for the treatment of previously treated
600:) used in 8 marketed products, covering
577:, collaboration was terminated in 2009)
2398:. event.webcasts.com. 13 September 2022
2326:
839:
2883:
2220:"PDL Biopharma to sell antibody plant"
2191:
1968:
1430:Relapsing remitting multiple sclerosis
701:relapsing remitting multiple sclerosis
172:Florian Schönharting and Lisa Drakeman
2891:Companies listed on Nasdaq Copenhagen
2620:
2438:
2296:
2294:
2270:
2164:
1989:
680:) for the treatment of all stages of
611:Proprietary, marketed with partners:
399:Genmab's technology is licensed from
2926:Danish companies established in 1999
2062:(Dynamic webpage). Nasdaq Nordic Ltd
829:diffuse cutaneous systemic sclerosis
686:amyloid light-chain (AL) amyloidosis
489:
455:Long Island Life Sciences Initiative
15:
2901:Pharmaceutical companies of Denmark
544:B-cell chronic lymphocytic leukemia
451:Biotechnology Industry Organization
13:
2946:Companies in the OMX Copenhagen 25
2906:Biotechnology companies of Denmark
2291:
411:The technology modifies the human
14:
2962:
2327:Carroll, John (7 December 2009).
2014:. GlobeNewswire. 14 February 2024
1969:Wright, Rob (December 30, 2019).
548:follicular non-Hodgkinâs lymphoma
2466:
1788:Gluten-free diet non-responsive
1361:) and DARZALEX FASPRO (subcu.) (
1080:Indolent NHL, pediatric patients
964:Most Advanced Development Phase
535:to co-develop and commercialize
86:
20:
2410:
2361:
2347:
2320:
2238:
2212:
2185:
2158:
2128:
1588:Most Advanced Development Phase
811:mimetic bi-specific antibody) (
516:
2951:Companies in the OMX Nordic 40
2896:Companies listed on the Nasdaq
2077:
2060:"GMAB, Genmab, (DK0010272202)"
2052:
2026:
1912:"Forward Pharma Board Members"
1846:"OMX Copenhagen 25 index info"
1838:
1:
2087:(Dynamic webpage). Nasdaq Inc
1832:
1734:Est. prim. completion 2024-05
1694:Est. prim. completion 2023-12
1363:daratumumab and hyaluronidase
899:diffuse large B-cell lymphoma
678:daratumumab and hyaluronidase
628:diffuse large B-cell lymphoma
394:
2302:"Glaxo buys stake in Genmab"
2169:. Central Jersey Briefcase.
2136:"Next Generation Technology"
1710:mimetic bispecific antibody)
1058:chronic lymphocytic leukemia
7:
2316:– via Newspapers.com.
2287:– via Newspapers.com.
2234:– via Newspapers.com.
2181:– via Newspapers.com.
1330:Approved Medicines/Products
845:Approved Medicines/Products
834:
588:The company has 8 approved
583:
459:James D. Watson Helix Award
156:; 25 years ago
40:. The specific problem is:
10:
2967:
1145:Non-small-cell lung cancer
781:) and epcoritamab (B-cell
716:non-small-cell lung cancer
419:
2772:
2721:
2655:
2486:
2072:Market: Nasdaq Copenhagen
978:Relapsed/refractory DLBCL
382:Copenhagen Stock Exchange
316:
306:
294:
282:
271:
228:
197:
187:
176:
168:
150:
140:
104:
94:
85:
77:Danish healthcare company
2248:. Genmed. Archived from
2142:. Genmab. Archived from
2112:. Genmab. Archived from
1633:Hepatocellular carcinoma
1227:Hematologic malignancies
785:and Relapsed/refractory
511:chief scientific officer
466:Brooklyn Park, Minnesota
302:DKK 4.352 billion (2023)
290:DKK 5.321 billion (2023)
2271:Staff (June 27, 2002).
2165:Staff (June 28, 2001).
2085:"Genmab A/S ADS (GMAB)"
2034:Form 8-K Current Report
1816:Multiple system atrophy
1654:Advanced or metastatic
1605:Advanced or Metastatic
1475:6% (Jan Van de Winkel)
1459:(under sublicense from
747:) for the treatment of
736:) for the treatment of
725:) for the treatment of
714:) for the treatment of
699:) for the treatment of
619:) for the treatment of
500:chief executive officer
480:came in February 2013.
1759:Relapsed/refractory HL
1527:Relapsed/refractory MM
738:relapsed/refractory MM
727:relapsed/refractory MM
660:Marketed by partners:
457:honored Genmab with a
2936:Dual-listed companies
2845:Svenska Handelsbanken
1743:Camidanlumab tesirine
672:) / Darzalex Faspro (
338:biotechnology company
278:16.474 billion (2023)
217:Deirdre P. Connelly (
2810:Hennes & Mauritz
2246:"2009 Annual Report"
2200:on December 13, 2010
2140:Science and Research
1384:2015 (iv), 2020 (sc)
1311:Relapsed/refractory
1056:Relapsed/refractory
1037:non-Hodgkin lymphoma
995:Relapsed/refractory
840:Proprietary Products
827:) and teprotumumab (
783:non-Hodgkin lymphoma
552:rheumatoid arthritis
437:Utrecht Science Park
430:Florian Schönharting
389:Global Select Market
47:improve this article
36:to meet Knowledge's
2713:Vestas Wind Systems
2596:Vestas Wind Systems
2252:on December 1, 2010
2116:on November 3, 2010
1975:Life Science Leader
1688:Sickle cell disease
1585:Disease indications
1467:Thyroid eye disease
1346:Disease indications
1094:50:50 Genmab/Seagen
997:Follicular lymphoma
975:50:50 Genmab/AbbVie
961:Disease indications
911:(tisotumab vedotin)
861:Disease indications
825:Sickle cell disease
787:Follicular lymphoma
749:thyroid eye disease
639:(tisotumab vedotin)
606:autoimmune diseases
384:in Denmark and the
308:Number of employees
206:Jan Van de Winkel (
189:Number of locations
82:
2146:on October 8, 2010
1166:endometrial cancer
1062:Richter's syndrome
869:EPKINLY/TEPKINLY (
615:Epkinly/Tepkinly (
80:
2878:
2877:
2614:
2613:
2496:A.P. MĂžller-MĂŠrsk
2473:OMX Copenhagen 25
1866:. 20 October 2018
1828:
1827:
1656:colorectal cancer
1611:Esophageal cancer
1566:
1565:
1322:
1321:
1088:Tisotumab vedotin
942:
941:
801:esophageal cancer
490:Executive history
358:Genmab U.S., Inc.
328:
327:
134:OMX Copenhagen 25
113:Nasdaq Copenhagen
75:
74:
67:
38:quality standards
29:This article may
2958:
2641:
2634:
2627:
2618:
2617:
2471:
2470:
2459:
2452:
2445:
2436:
2435:
2430:
2429:
2427:
2425:
2414:
2408:
2407:
2405:
2403:
2392:
2381:
2380:
2378:
2376:
2365:
2359:
2358:
2351:
2345:
2344:
2342:
2340:
2324:
2318:
2317:
2315:
2313:
2306:The Boston Globe
2298:
2289:
2288:
2286:
2284:
2268:
2262:
2261:
2259:
2257:
2242:
2236:
2235:
2233:
2231:
2216:
2210:
2209:
2207:
2205:
2189:
2183:
2182:
2180:
2178:
2167:"Business Notes"
2162:
2156:
2155:
2153:
2151:
2132:
2126:
2125:
2123:
2121:
2106:
2100:
2099:
2094:
2092:
2081:
2075:
2074:
2069:
2067:
2056:
2050:
2049:
2047:
2045:
2030:
2024:
2023:
2021:
2019:
2008:
1987:
1986:
1984:
1982:
1966:
1927:
1926:
1924:
1922:
1908:
1902:
1901:
1899:
1897:
1892:. Marketscreener
1886:"Marketscreener"
1882:
1876:
1875:
1873:
1871:
1856:
1850:
1849:
1842:
1755:ADC Therapeutics
1573:
1572:
1379:Multiple myeloma
1337:Approved Product
1334:
1333:
1313:Hodgkin lymphoma
1300:DuoBody-CD3xCD20
1259:(GEN1053/BNT313)
1235:DuoBody-CD3xB7H4
1194:(GEN1042/BNT312)
1126:(GEN1046/BNT311)
1016:First line DLBCL
949:
948:
852:Approved Product
849:
848:
795:), amivantamab (
682:multiple myeloma
604:indications and
569:
565:
561:
557:
529:GlaxoSmithKline:
324:
285:Operating income
242:EPKINLY/TEPKINLY
164:
162:
157:
90:
83:
79:
70:
63:
59:
56:
50:
24:
23:
16:
2966:
2965:
2961:
2960:
2959:
2957:
2956:
2955:
2881:
2880:
2879:
2874:
2768:
2717:
2651:
2645:
2615:
2610:
2501:Bavarian Nordic
2482:
2480:(December 2023)
2465:
2463:
2433:
2423:
2421:
2416:
2415:
2411:
2401:
2399:
2394:
2393:
2384:
2374:
2372:
2367:
2366:
2362:
2353:
2352:
2348:
2338:
2336:
2325:
2321:
2311:
2309:
2300:
2299:
2292:
2282:
2280:
2269:
2265:
2255:
2253:
2244:
2243:
2239:
2229:
2227:
2218:
2217:
2213:
2203:
2201:
2190:
2186:
2176:
2174:
2163:
2159:
2149:
2147:
2134:
2133:
2129:
2119:
2117:
2108:
2107:
2103:
2090:
2088:
2083:
2082:
2078:
2065:
2063:
2058:
2057:
2053:
2043:
2041:
2032:
2031:
2027:
2017:
2015:
2010:
2009:
1990:
1980:
1978:
1967:
1930:
1920:
1918:
1910:
1909:
1905:
1895:
1893:
1884:
1883:
1879:
1869:
1867:
1858:
1857:
1853:
1844:
1843:
1839:
1835:
1806:Alpha-Synuclein
1763:
1745:
1733:
1705:
1693:
1571:
1458:
1392:DARZALEX FASPRO
1357:DARZALEX (iv) (
1332:
1327:
1301:
1282:
1258:
1236:
1215:
1193:
1125:
1097:Cervical cancer
947:
934:Cervical cancer
847:
842:
837:
790:
771:cervical cancer
768:
650:cervical cancer
586:
568:US$ 135 million
567:
564:US$ 2.1 billion
563:
560:US$ 359 million
559:
556:US$ 102 million
555:
533:GlaxoSmithKline
519:
496:Donald Drakeman
492:
422:
397:
354:The Netherlands
320:
309:
299:
287:
264:
260:
256:
252:
248:
244:
240:
238:DARZALEX FASPRO
236:
224:
200:
190:
160:
158:
155:
132:
119:
109:
78:
71:
60:
54:
51:
44:
25:
21:
12:
11:
5:
2964:
2954:
2953:
2948:
2943:
2938:
2933:
2928:
2923:
2918:
2913:
2908:
2903:
2898:
2893:
2876:
2875:
2873:
2872:
2867:
2862:
2857:
2852:
2847:
2842:
2837:
2832:
2827:
2822:
2817:
2812:
2807:
2802:
2797:
2792:
2787:
2782:
2776:
2774:
2770:
2769:
2767:
2766:
2761:
2756:
2751:
2746:
2741:
2736:
2731:
2725:
2723:
2719:
2718:
2716:
2715:
2710:
2705:
2700:
2695:
2690:
2685:
2680:
2675:
2670:
2665:
2659:
2657:
2653:
2652:
2644:
2643:
2636:
2629:
2621:
2612:
2611:
2609:
2608:
2603:
2601:Zealand Pharma
2598:
2593:
2588:
2583:
2578:
2573:
2568:
2563:
2558:
2553:
2548:
2543:
2538:
2533:
2528:
2523:
2518:
2513:
2508:
2503:
2498:
2493:
2487:
2484:
2483:
2462:
2461:
2454:
2447:
2439:
2432:
2431:
2409:
2382:
2360:
2346:
2319:
2290:
2277:The Nutley Sun
2263:
2237:
2211:
2184:
2157:
2127:
2110:"About Genmab"
2101:
2097:Market: Nasdaq
2076:
2051:
2025:
1988:
1928:
1916:Forward Pharma
1903:
1890:Marketscrenner
1877:
1851:
1836:
1834:
1831:
1826:
1825:
1822:
1819:
1813:
1808:
1803:
1799:
1798:
1795:
1792:
1790:Celiac disease
1786:
1781:
1776:
1770:
1769:
1766:
1760:
1757:
1752:
1747:
1739:
1738:
1735:
1730:
1725:
1720:
1711:
1699:
1698:
1695:
1690:
1681:
1676:
1671:
1665:
1664:
1661:
1658:
1652:
1649:
1646:
1642:
1641:
1638:
1635:
1630:
1627:
1624:
1620:
1619:
1616:
1613:
1603:
1600:
1597:
1593:
1592:
1589:
1586:
1583:
1580:
1577:
1570:
1567:
1564:
1563:
1560:
1557:
1554:
1551:
1545:
1537:
1536:
1533:
1530:
1524:
1521:
1515:
1507:
1506:
1503:
1500:
1497:
1494:
1485:
1477:
1476:
1473:
1470:
1464:
1453:
1448:
1440:
1439:
1436:
1433:
1427:
1422:
1419:
1411:
1410:
1407:
1404:
1402:AL Amyloidosis
1399:
1396:
1393:
1389:
1388:
1385:
1382:
1376:
1371:
1366:
1354:
1353:
1350:
1347:
1344:
1341:
1338:
1331:
1328:
1326:
1323:
1320:
1319:
1316:
1315:(HL) & NHL
1309:
1306:
1303:
1297:
1296:
1293:
1290:
1287:
1284:
1278:
1277:
1274:
1271:
1265:
1260:
1254:
1253:
1250:
1247:
1244:
1238:
1232:
1231:
1228:
1225:
1222:
1217:
1211:
1210:
1207:
1204:
1201:
1195:
1189:
1188:
1185:
1182:
1179:
1176:
1172:
1171:
1168:
1162:
1159:
1156:
1152:
1151:
1148:
1142:
1136:
1127:
1121:
1120:
1117:
1112:
1109:
1106:
1102:
1101:
1098:
1095:
1092:
1089:
1085:
1084:
1081:
1078:
1075:
1072:
1068:
1067:
1064:
1054:
1051:
1048:
1044:
1043:
1040:
1031:
1028:
1025:
1021:
1020:
1017:
1014:
1011:
1008:
1004:
1003:
1000:
993:
990:
987:
983:
982:
979:
976:
973:
970:
966:
965:
962:
959:
956:
953:
946:
943:
940:
939:
936:
924:
918:
913:
906:
905:
902:
889:
883:
874:
866:
865:
864:Approval Year
862:
859:
856:
853:
846:
843:
841:
838:
836:
833:
797:gastric cancer
775:ovarian cancer
757:
756:
741:
730:
719:
708:
693:
658:
657:
635:
585:
582:
518:
515:
491:
488:
453:(BIO) and the
421:
418:
396:
393:
326:
325:
318:
314:
313:
310:
307:
304:
303:
300:
295:
292:
291:
288:
283:
280:
279:
273:
269:
268:
230:
226:
225:
223:
222:
215:
203:
201:
198:
195:
194:
191:
188:
185:
184:
178:
174:
173:
170:
166:
165:
152:
148:
147:
142:
138:
137:
110:
105:
102:
101:
96:
92:
91:
76:
73:
72:
28:
26:
19:
9:
6:
4:
3:
2:
2963:
2952:
2949:
2947:
2944:
2942:
2939:
2937:
2934:
2932:
2931:Danish brands
2929:
2927:
2924:
2922:
2919:
2917:
2914:
2912:
2909:
2907:
2904:
2902:
2899:
2897:
2894:
2892:
2889:
2888:
2886:
2871:
2868:
2866:
2863:
2861:
2858:
2856:
2855:Swedish Match
2853:
2851:
2848:
2846:
2843:
2841:
2838:
2836:
2833:
2831:
2828:
2826:
2823:
2821:
2818:
2816:
2813:
2811:
2808:
2806:
2803:
2801:
2798:
2796:
2793:
2791:
2788:
2786:
2783:
2781:
2778:
2777:
2775:
2771:
2765:
2762:
2760:
2757:
2755:
2752:
2750:
2747:
2745:
2742:
2740:
2737:
2735:
2732:
2730:
2727:
2726:
2724:
2720:
2714:
2711:
2709:
2706:
2704:
2701:
2699:
2698:GN Store Nord
2696:
2694:
2691:
2689:
2686:
2684:
2681:
2679:
2676:
2674:
2671:
2669:
2666:
2664:
2661:
2660:
2658:
2654:
2649:
2648:OMX Nordic 40
2642:
2637:
2635:
2630:
2628:
2623:
2622:
2619:
2607:
2604:
2602:
2599:
2597:
2594:
2592:
2589:
2587:
2586:Royal Unibrew
2584:
2582:
2579:
2577:
2574:
2572:
2569:
2567:
2564:
2562:
2559:
2557:
2554:
2552:
2549:
2547:
2544:
2542:
2541:GN Store Nord
2539:
2537:
2534:
2532:
2529:
2527:
2524:
2522:
2519:
2517:
2514:
2512:
2509:
2507:
2504:
2502:
2499:
2497:
2494:
2492:
2489:
2488:
2485:
2481:
2478:
2475:companies of
2474:
2469:
2460:
2455:
2453:
2448:
2446:
2441:
2440:
2437:
2419:
2413:
2397:
2391:
2389:
2387:
2370:
2364:
2356:
2350:
2334:
2333:FierceBiotech
2330:
2323:
2307:
2303:
2297:
2295:
2278:
2274:
2267:
2251:
2247:
2241:
2225:
2221:
2215:
2199:
2195:
2188:
2172:
2168:
2161:
2145:
2141:
2137:
2131:
2115:
2111:
2105:
2098:
2086:
2080:
2073:
2061:
2055:
2039:
2035:
2029:
2013:
2007:
2005:
2003:
2001:
1999:
1997:
1995:
1993:
1977:. VertMarkets
1976:
1972:
1965:
1963:
1961:
1959:
1957:
1955:
1953:
1951:
1949:
1947:
1945:
1943:
1941:
1939:
1937:
1935:
1933:
1917:
1913:
1907:
1891:
1887:
1881:
1865:
1861:
1855:
1847:
1841:
1837:
1830:
1823:
1820:
1817:
1814:
1812:
1809:
1807:
1804:
1801:
1800:
1796:
1793:
1791:
1787:
1785:
1782:
1780:
1777:
1775:
1772:
1771:
1767:
1761:
1758:
1756:
1753:
1751:
1748:
1744:
1741:
1740:
1736:
1731:
1729:
1728:Haemophilia A
1726:
1724:
1721:
1719:
1715:
1712:
1709:
1704:
1701:
1700:
1696:
1691:
1689:
1685:
1682:
1680:
1677:
1675:
1672:
1670:
1667:
1666:
1662:
1659:
1657:
1653:
1650:
1647:
1644:
1643:
1639:
1636:
1634:
1631:
1628:
1625:
1622:
1621:
1617:
1614:
1612:
1608:
1604:
1601:
1598:
1595:
1594:
1590:
1587:
1584:
1581:
1578:
1575:
1574:
1561:
1558:
1555:
1552:
1549:
1546:
1543:
1539:
1538:
1534:
1531:
1528:
1525:
1522:
1519:
1516:
1513:
1509:
1508:
1504:
1501:
1498:
1495:
1493:
1489:
1486:
1483:
1479:
1478:
1474:
1471:
1468:
1465:
1462:
1457:
1454:
1452:
1449:
1446:
1442:
1441:
1437:
1434:
1431:
1428:
1426:
1423:
1420:
1417:
1413:
1412:
1408:
1405:
1403:
1400:
1397:
1394:
1391:
1390:
1386:
1383:
1380:
1377:
1375:
1372:
1370:
1367:
1364:
1360:
1356:
1355:
1351:
1349:Approval Year
1348:
1345:
1342:
1339:
1336:
1335:
1317:
1314:
1310:
1307:
1304:
1299:
1298:
1294:
1291:
1288:
1285:
1280:
1279:
1275:
1272:
1270:
1267:50:50 Genmab/
1266:
1264:
1261:
1257:HexaBody-CD27
1256:
1255:
1251:
1248:
1245:
1243:
1239:
1234:
1233:
1229:
1226:
1223:
1221:
1218:
1214:HexaBody-CD38
1213:
1212:
1208:
1205:
1202:
1199:
1196:
1191:
1190:
1186:
1183:
1180:
1177:
1174:
1173:
1169:
1167:
1163:
1160:
1157:
1154:
1153:
1149:
1146:
1143:
1141:
1138:50:50 Genmab/
1137:
1135:
1131:
1128:
1123:
1122:
1118:
1116:
1113:
1110:
1107:
1104:
1103:
1099:
1096:
1093:
1090:
1087:
1086:
1082:
1079:
1076:
1073:
1070:
1069:
1065:
1063:
1059:
1055:
1052:
1049:
1046:
1045:
1041:
1038:
1035:
1032:
1029:
1026:
1023:
1022:
1018:
1015:
1012:
1009:
1006:
1005:
1001:
998:
994:
991:
988:
985:
984:
980:
977:
974:
971:
968:
967:
963:
960:
957:
954:
951:
950:
937:
935:
932:
928:
925:
923:
920:50:50 Genmab/
919:
917:
914:
912:
908:
907:
903:
900:
897:
893:
890:
888:
885:50:50 Genmab/
884:
882:
878:
875:
872:
868:
867:
863:
860:
857:
854:
851:
850:
832:
830:
826:
822:
818:
814:
813:Haemophilia A
810:
806:
802:
798:
794:
793:blood cancers
788:
784:
780:
776:
772:
766:
762:
754:
750:
746:
742:
739:
735:
731:
728:
724:
720:
717:
713:
709:
706:
702:
698:
694:
691:
687:
683:
679:
675:
671:
667:
663:
662:
661:
655:
651:
648:
644:
640:
636:
633:
629:
626:
622:
618:
614:
613:
612:
609:
607:
603:
599:
595:
591:
581:
578:
576:
571:
553:
549:
545:
542:
541:CD20 positive
538:
534:
530:
526:
523:
514:
512:
508:
503:
501:
497:
487:
484:
481:
479:
475:
471:
470:PDL BioPharma
467:
462:
460:
456:
452:
449:In 2005, the
447:
444:
442:
438:
433:
431:
427:
417:
414:
409:
405:
402:
392:
390:
387:
383:
379:
375:
371:
367:
363:
359:
355:
351:
347:
343:
339:
336:
332:
323:
319:
315:
311:
305:
301:
298:
293:
289:
286:
281:
277:
274:
270:
267:
263:
259:
255:
251:
247:
243:
239:
234:
231:
227:
220:
216:
213:
209:
205:
204:
202:
196:
192:
186:
182:
179:
175:
171:
167:
153:
149:
146:
145:Biotechnology
143:
139:
135:
130:
126:
122:
118:
114:
111:
108:
103:
100:
97:
93:
89:
84:
69:
66:
58:
48:
43:
39:
35:
34:
27:
18:
17:
2703:Novo Nordisk
2692:
2566:Novo Nordisk
2535:
2479:
2422:. Retrieved
2412:
2402:14 September
2400:. Retrieved
2373:. Retrieved
2363:
2349:
2337:. Retrieved
2332:
2322:
2310:. Retrieved
2305:
2281:. Retrieved
2276:
2266:
2254:. Retrieved
2250:the original
2240:
2228:. Retrieved
2224:Star Tribune
2223:
2214:
2202:. Retrieved
2198:the original
2187:
2175:. Retrieved
2171:Courier News
2170:
2160:
2148:. Retrieved
2144:the original
2139:
2130:
2118:. Retrieved
2114:the original
2104:
2096:
2089:. Retrieved
2079:
2071:
2064:. Retrieved
2054:
2042:. Retrieved
2028:
2016:. Retrieved
1979:. Retrieved
1974:
1919:. Retrieved
1915:
1906:
1894:. Retrieved
1889:
1880:
1868:. Retrieved
1863:
1854:
1840:
1829:
1723:Novo Nordisk
1445:teprotumumab
1292:Solid tumors
1273:Solid tumors
1249:Solid tumors
1206:Solid tumors
1192:Tecaginlimab
1184:Solid tumors
1115:Solid tumors
1060:(CLL) &
958:Developed by
858:Developed by
779:solid tumors
765:pre-clinical
758:
745:teprotumumab
659:
610:
587:
579:
572:
528:
527:
521:
520:
517:Partnerships
504:
493:
485:
482:
463:
448:
445:
434:
423:
410:
406:
398:
369:
357:
345:
330:
329:
312:2,204 (2023)
214:, from 2010)
177:Headquarters
95:Company type
61:
52:
45:Please help
41:
30:
2795:Atlas Copco
2790:AstraZeneca
2764:UPM-Kymmene
2683:Danske Bank
2673:Chr. Hansen
2561:Nordea Bank
2521:Danske Bank
2511:Chr. Hansen
2424:11 December
1921:14 November
1896:14 November
1870:14 November
1774:Ordesekimab
1708:Factor VIII
1645:Amivantamab
1623:Amivantamab
1596:Amivantamab
1542:talquetamab
1512:teclistamab
1482:amivantamab
1480:RYBREVANT (
1359:daratumumab
1286:Undisclosed
1124:Acasunlimab
969:Epcoritamab
871:epcoritamab
809:Factor VIII
734:teclistamab
723:talquetamab
712:amivantamab
710:Rybrevant (
670:daratumumab
617:epcoritamab
391:in the US.
370:Genmab K.K.
346:Genmab B.V.
219:Board chair
49:if you can.
2885:Categories
2785:Assa Abloy
2759:Stora Enso
2551:Jyske Bank
2256:3 November
2204:17 January
2150:3 November
2120:3 November
1864:Berlingske
1833:References
1802:Lu AF82422
1746:(ADCT-301)
1674:selectin P
1669:Inclacumab
1599:EGFR, cMet
1591:Royalties
1510:TECVAYLI (
1416:ofatumumab
1414:Kesimpta (
1409:As for MM
1352:Royalties
931:metastatic
896:refractory
817:inclacumab
732:Tecvayli (
697:ofatumumab
695:Kesimpta (
664:Darzalex (
647:metastatic
625:refractory
598:bispecific
594:monoclonal
590:antibodies
537:ofatumumab
395:Technology
342:Copenhagen
331:Genmab A/S
322:Genmab.com
297:Net income
199:Key people
181:Copenhagen
81:Genmab A/S
2678:Coloplast
2668:Carlsberg
2650:companies
2571:Novozymes
2516:Coloplast
2506:Carlsberg
2339:6 January
2335:. Questex
2312:6 January
2283:6 January
2230:6 January
2177:6 January
2044:6 January
1981:6 January
1443:TEPEZZA (
1305:CD3, CD20
1237:(GEN1047)
1216:(GEN3014)
1164:Advanced
972:CD3, CD20
927:Recurrent
743:Tepezza (
740:(Janssen)
729:(Janssen)
643:recurrent
630:(DLBCL) (
507:President
474:write-off
362:Princeton
250:RYBREVANT
208:president
183:, Denmark
136:component
107:Traded as
2850:Swedbank
2820:Investor
2800:Ericsson
2581:Rockwool
2038:Form 8-K
2018:11 March
1811:Lundbeck
1540:TALVEY (
1425:Novartis
1283:(BNT322)
1269:BioNTech
1140:BioNTech
892:Relapsed
835:Pipeline
761:clinical
721:Talvey (
705:Novartis
621:Relapsed
584:Products
258:TECVAYLI
246:Kesimpta
233:DARZALEX
229:Products
193:4 (2023)
141:Industry
55:May 2024
31:require
2825:Sandvik
2815:Hexagon
2722:Finland
2656:Denmark
2576:Pandora
2477:Denmark
2091:9 March
2066:9 March
1607:Gastric
1602:Janssen
1576:Product
1553:Janssen
1523:Janssen
1496:Janssen
1398:Janssen
1374:Janssen
1302:GEN3017
1281:GEN1056
1200:, 4-1BB
1147:(NSCLC)
1039:(B-NHL)
952:Product
909:Tivdak
901:(DLBCL)
753:Horizon
690:Janssen
637:Tivdak
441:Utrecht
426:Medarex
420:History
401:Medarex
350:Utrecht
317:Website
272:Revenue
262:TEPEZZA
169:Founder
159: (
151:Founded
123::
115::
33:cleanup
2805:Essity
2773:Sweden
2749:Nordea
2729:Fortum
2708:Ărsted
2693:Genmab
2606:Ărsted
2536:Genmab
2526:Demant
2375:20 May
1784:Sanofi
1765:years.
1679:Pfizer
1618:8-10%
1579:Target
1562:~5-6%
1548:GPRC5D
1535:~5-6%
1529:(RRMM)
1505:8-10%
1451:IGF-1R
1432:(RRMS)
1340:Target
1308:Genmab
1246:Genmab
1034:B-cell
955:Target
922:Seagen
887:AbbVie
855:Target
654:Seagen
632:AbbVie
602:cancer
575:IGF-1R
522:Amgen:
478:Baxter
386:NASDAQ
368:, and
335:Danish
266:Tivdak
254:TALVEY
121:Nasdaq
99:Public
2870:Volvo
2865:Telia
2860:Tele2
2754:Sampo
2744:Nokia
2739:Neste
1818:(MSA)
1779:IL-15
1550:, CD3
1520:, CD3
1499:NSCLC
1469:(TED)
1461:Roche
1456:Amgen
1240:CD3,
1187:I/II
1134:4-1BB
1130:PD-L1
1066:I/II
938:2021
904:2023
468:from
378:Japan
374:Tokyo
333:is a
2734:KONE
2663:Ambu
2591:Tryg
2491:Ambu
2426:2022
2404:2022
2377:2023
2341:2020
2314:2020
2285:2020
2258:2010
2232:2020
2206:2011
2179:2020
2152:2010
2122:2010
2093:2022
2068:2022
2046:2020
2020:2024
1983:2020
1923:2020
1898:2020
1872:2020
1750:CD25
1714:FIXa
1703:Mim8
1660:I/II
1559:2023
1556:RRMM
1532:2022
1518:BCMA
1502:2021
1492:cMet
1488:EGFR
1472:2020
1438:10%
1435:2020
1421:CD20
1406:2021
1395:CD38
1381:(MM)
1369:CD38
1263:CD27
1242:B7H4
1220:CD38
1198:CD40
1100:III
1019:III
1002:III
999:(FL)
981:III
881:CD20
805:Mim8
799:and
777:and
763:and
596:and
413:IgG4
210:and
161:1999
154:1999
125:GMAB
117:GMAB
2840:SKF
2835:SEB
2830:SCA
2780:ABB
2688:DSV
2556:NKT
2546:ISS
2531:DSV
1732:III
1692:III
1686:in
1684:VOC
1609:or
1252:II
1230:II
1209:II
1170:II
1150:II
1119:II
1042:II
929:or
877:CD3
831:).
823:in
821:VOC
815:),
803:),
676:) (
668:) (
645:or
372:in
366:USA
360:in
348:in
276:DKK
212:CEO
129:ADR
2887::
2385:^
2331:.
2304:.
2293:^
2275:.
2222:.
2138:.
2095:.
2070:.
1991:^
1973:.
1931:^
1914:.
1888:.
1862:.
1824:-
1821:II
1797:-
1794:II
1762:II
1718:FX
1716:,
1663:"
1640:"
1637:II
1615:II
1490:,
1318:I
1295:I
1276:I
1132:,
1091:TF
1083:I
916:TF
879:,
789:).
773:,
674:SC
666:IV
608:.
550:,
546:,
461:.
376:,
364:,
356:,
352:,
2640:e
2633:t
2626:v
2458:e
2451:t
2444:v
2428:.
2406:.
2379:.
2357:.
2343:.
2260:.
2208:.
2154:.
2124:.
2048:.
2036:(
2022:.
1985:.
1925:.
1900:.
1874:.
1848:.
1706:(
1651:"
1648:"
1629:"
1626:"
1544:)
1514:)
1484:)
1463:)
1447:)
1418:)
1365:)
1289:"
1203:"
1181:"
1178:"
1175:"
1161:"
1158:"
1155:"
1111:"
1108:"
1105:"
1077:"
1074:"
1071:"
1053:"
1050:"
1047:"
1030:"
1027:"
1024:"
1013:"
1010:"
1007:"
992:"
989:"
986:"
894:/
873:)
819:(
807:(
755:)
751:(
707:)
703:(
692:)
688:(
656:)
652:(
634:)
623:/
592:(
235:/
221:)
163:)
131:)
127:(
68:)
62:(
57:)
53:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
